Related Experiment Videos
[Early therapeutic intervention in heart failure]
Insights
Early intervention for heart failure, particularly addressing left ventricular hypertrophy (LVH) with ACE-inhibitors, may improve outcomes. This approach targets the disease before severe symptoms manifest, potentially reducing mortality.
Area of Science:
- Cardiology and Cardiovascular Diseases
- Pharmacology and Therapeutics
Context:
- Despite advances in treating moderate to severe heart failure with vasodilators, digitalis, and diuretics, mortality rates remain high.
- Left ventricular hypertrophy (LVH) is a primary early pathophysiological change in heart failure, linked to hypertension, coronary artery disease, aging, and obesity.
- LVH can progress to diastolic/systolic heart failure, ischemia, arrhythmias, and sudden cardiac death.
Purpose:
- To investigate the potential benefits of initiating treatment at earlier stages of heart failure.
- To explore the role of angiotensin-converting enzyme (ACE) inhibitors in reducing left ventricular hypertrophy (LVH).
- To evaluate if early intervention with ACE inhibitors in asymptomatic heart failure patients improves prognosis, as suggested by SAVE and SOLVD-prevention trials.
Summary:
- ACE inhibitors have demonstrated the ability to reduce LVH within one month.
- Large trials like SAVE and SOLVD-prevention are assessing the efficacy of early ACE inhibitor treatment in asymptomatic heart failure.
- This strategy aims to improve patient outcomes by intervening before significant disease progression.
Impact:
- Early intervention targeting LVH with ACE inhibitors could significantly reduce heart failure mortality and morbidity.
- This approach may shift treatment paradigms towards proactive management of cardiovascular risk factors.
- Findings from ongoing trials will inform clinical guidelines for managing early-stage heart failure and related conditions.
Abstract:
During the past years, several large trials (Consensus, VHEFT I and II, SOLVD) have shown a significant reduction of mortality in patients with moderate and severe heart failure. However, despite effective treatment with vasodilators, digitalis and diuretics mortality in these patients remains unacceptable high. It seems logic, to state treatment at an earlier stage of the disease to achieve more benefit. The main early pathophysiological disturbance is left ventricular hypertrophy, resulting from hypertension, coronary artery disease, increasing age and obesity. On the long run, LVH may lead to diastolic and systolic heart failure, myocardial ischemia, arrhythmias and sudden death. With ACE-inhibitors LVH can be reduced within 1 month of treatment. The large SAVE- and SOLVD-prevention trials will show, whether this early intervention will improve proposis in patients with asymptomatic heart failure.